Evolution in the management of acute liver failure-associated aplastic anaemia in children: a single centre experience |
| |
Authors: | Hadzić Nedim Height Susan Ball Sarah Rela Mohamed Heaton Nigel D Veys Paul Mieli-Vergani Giorgina |
| |
Affiliation: | Institute of Liver Studies, King's College London School of Medicine at King's College, London, UK. nedim.hadzic@kcl.ac.uk |
| |
Abstract: | BACKGROUND/AIMS: Bone marrow failure (BMF) is a potentially life-threatening complication of acute liver failure (ALF). METHODS: To investigate prevalence and evolving management of BMF associated with ALF, we reviewed all cases seen in our centre over 17 years. BMF was classified as: (a) bone marrow hypoplasia, (b) severe aplastic anaemia (SAA) and (c) very severe aplastic anaemia (VSAA), using standard criteria. We compared outcomes in children receiving: (1) medical treatment only with or without immunomodulation (anti-lymphocyte globulin, calcineurin inhibitors, G-CSF); (2) medical treatment with or without immunomodulation plus liver transplantation (LT); (3) haematopoietic stem cell transplantation (HSCT). RESULTS: Of 213 patients with ALF, 20 [(9.4%); 14 (70%) boys] developed BMF after a median of 1 month (range, 0.5 to 7). Seven had VSAA, 7 SAA and 6 bone marrow hypoplasia. Five children were treated medically, including 3 by immunomodulation; 10 (50%) received LT, with immunomodulation in 6; 5 (25%) received HSCT, in one after LT. Four (20%) children died, only one as consequence of AA. There was no difference in recovery, complication rates or outcome among the three groups. CONCLUSIONS: Aggressive management of ALF-associated AA, including immunomodulation, HSCT and LT, is successful in most cases. HSCT has the advantage of removing the risk of late clonal disorders. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|